StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
CGTX

Cognition Therapeutics, Inc.

CGTX Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗
$0.89
-0.02 -2.67%

Key statistics

from XBRL data in SEC filings
Market cap
$79.8M
Revenue (TTM)
Net income (TTM)
-$19.6M
EPS (TTM)
$-0.23
P/E ratio
Dividend yield
Free cash flow
-$24.6M
Cash
$31.1M
Total assets
$36.1M
Gross margin
52-week range
$0.55 – $3.83

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Other events Jun 24, 2026 8-K Shareholder vote results Jun 18, 2026 8-K Regulation FD disclosure Jun 4, 2026 8-K Other events May 21, 2026 10-Q Quarter ended 2026-03-31 May 8, 2026 8-K Results of operations (earnings release) May 7, 2026 10-K Fiscal year ended 2025-12-31 Mar 26, 2026 8-K Results of operations (earnings release); Regulation FD disclosure Mar 26, 2026 8-K Other events Mar 2, 2026 8-K Other events Jan 27, 2026 8-K Entered a material agreement; Terminated a material agreement Dec 18, 2025 10-Q Quarter ended 2025-09-30 Nov 6, 2025 8-K Results of operations (earnings release) Nov 6, 2025 8-K Other events Sep 15, 2025 8-K Entered a material agreement Aug 28, 2025 8-K Other events Aug 26, 2025 8-K Results of operations (earnings release) Aug 7, 2025 10-Q Quarter ended 2025-06-30 Aug 7, 2025 8-K Shareholder vote results Jun 20, 2025 8-K Other events Jun 3, 2025 8-K Other events Jun 2, 2025 8-K Other events May 8, 2025 10-Q Quarter ended 2025-03-31 May 7, 2025 8-K Results of operations (earnings release) May 7, 2025 10-K Fiscal year ended 2024-12-31 Mar 20, 2025 8-K Results of operations (earnings release) Mar 20, 2025 8-K Other events Mar 12, 2025 8-K Other events Feb 26, 2025 8-K Other events Jan 28, 2025 8-K Regulation FD disclosure Jan 13, 2025 8-K Other events Dec 18, 2024 10-Q Quarter ended 2024-09-30 Nov 13, 2024 8-K Results of operations (earnings release) Nov 13, 2024 8-K Regulation FD disclosure Oct 1, 2024 8-K Delisting notice or listing-rule failure Sep 13, 2024 8-K Regulation FD disclosure Aug 28, 2024 10-Q Quarter ended 2024-06-30 Aug 8, 2024 8-K Results of operations (earnings release) Aug 8, 2024 8-K Other events Jul 29, 2024 8-K Shareholder vote results Jun 7, 2024